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Abstract
Delayed hemolytic transfusion reactions (DHTR) are potentially life-threatening complications
observed in patients with sickle cell disease. We review the clinical features, pathophysiology,
laboratory evaluation, and management of this complication. It is important that DHTR be included
in the differential diagnosis of acute pain episodes following a red blood cell transfusion in a patient
with sickle cell disease.
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Background
Sickle cell disease (SCD), including sickle cell anemia and the various compound heterozygote
genotypes, is characterized by the presence of a chronic hemolytic anemia and vaso-occlusive
complications. Recently, the clinical manifestations of SCD have been described to fall into
two partially overlapping sub-phenotypes: hemolytic and vaso-occlusive sub-phenotypes.1 As
a result of its associated complications, patients with SCD frequently require red blood cell
(RBC) transfusion therapy.2, 3 RBC transfusion therapy is an important treatment modality in
patients with SCD. It is generally indicated to increase oxygen carrying capacity or to improve
the rheological properties of blood in these patients.3 Patients may benefit from simple or
exchange RBC transfusion to ameliorate or prevent a myriad of SCD-associated complications.
Absolute indications for transfusion in SCD are few, and may include new neurologic
symptoms including stroke, acute splenic or hepatic sequestration crises, aplastic crises, or
hemodynamic/cardiovascular compromise.3 The hemoglobin concentration, by itself, should
not be considered a reason for transfusion.3 This is because patients with SCD routinely have
relatively low hemoglobin values and most of these patients tolerate their anemia quite well.
The exposure to multiple RBC transfusions increases the likelihood of complications of such
therapy. In addition to the risks of infectious complications and iron overload, SCD patients
may develop delayed hemolytic transition reactions (DHTR) frequently related to
alloimmunization,2, 4 a serious complication due to the development of clinically significant
antibodies to RBC antigens. DHTR represents an important and potentially life-threatening
complication of RBC transfusion in patients with SCD.
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In this review, we present a synthesis of the current understanding of risk factors for
alloimmunization, as well as the clinical presentation, pathophysiology, appropriate laboratory
investigation, and clinical management of DHTR in SCD.
Prevalence of Alloimmunization and Risk Factors
Because RBC transfusion in SCD patients is associated with multiple complications, judicious
use of transfusion therapy is especially important. A detailed discussion of these complications
is beyond the scope of this paper. Among these complications is an increased rate of
alloimmunization compared with other chronically transfused populations.2, 4 The rate of
alloimmunization in SCD has been reported to be as high as 19% to 47% in adult patients.3,
5–7 Antibodies may become rapidly undetectable in a substantial number of patients,4 which
may result in an underestimation of the prevalence of this complication.
Alloimmunization appears to be related to the number of RBC transfusions received, older age
at time of first transfusion, and gender, with women having a higher rate than men, in large
part due to more frequent transfusions in women.7 In patients with SCD, racial differences
between recipient (predominantly African-Americans) and donor (predominantly Caucasians)
expression of RBC antigens are thought to contribute to the increased risk of alloimmunization.
8, 9 In a report comparing red cell phenotypes of African-American patients and blood bank
donors, donors had a significantly greater incidence of the antigens E, C, Kell, Fya, Fyb, and
Jkb.8
It remains unclear why some patients mount strong alloantibody responses following initial
RBC transfusions, while others do not despite multiple transfusions. Associations of HLA
types with alloimmunization in multiply transfused SCD patients have been described.10, 11
More recently, a case-controlled study demonstrated associations of alloimmunization with
particular HLA subtypes.12 The HLA-DRB1*1503 allele was associated with an increased risk
of alloimmunization (OR 2.02, p=0.039), while the HLA-DRB1*0901 allele appeared to confer
protection from developing alloantibodies (OR 0.13, p=0.008). There is some evidence in
murine models that inflammation plays a complex regulatory role in RBC alloimmunization.
13 With the abundant evidence that SCD is characterized by chronic inflammation,14, 15 it is
possible that inflammation may play a role in the high rate of alloimmunization observed in
these patients. However, there are, to date, no published data in SCD patients.
Clinical features
The clinical presentation of a DHTR in SCD may be quite similar to that of a sickle cell pain
crisis, with or without features of an “aplastic crisis.” 6, 16–18 As a result, the diagnosis of a
DHTR may be delayed because the anemia and pain are attributed to a pain crisis with
“hyperhemolysis.” Indeed, the components of the sickle cell hemolytic transfusion reaction
syndrome have been described (Table 1).19 In addition to the manifestations of acute or delayed
hemolysis, patients typically exhibit symptoms of a pain crisis, marked reticulocytopenia (a
decrease from the patient’s usual absolute reticulocyte count), and may develop a more severe
anemia following transfusion than was present before.
In light of these clinical features, it is important to include DHTR in the differential diagnosis
of any SCD patient presenting with features of a typical or atypical pain episode and to inquire
about recent transfusion history, particularly in patients who were recently hospitalized.
Although patients often have multiple RBC alloantibodies or autoantibodies making it difficult
to find compatible RBC units, occasionally no alloantibodies may be detected and serologic
studies may not provide an explanation for the DHTR. As patients recover, they exhibit a
reticulocytosis and improvement in hemoglobin.19
Scheunemann and Ataga Page 2














The mechanism of the worsening anemia that occurs following RBC transfusion remains
controversial (Table 2). By performing a hemoglobin electrophoresis, it is easy to show that
donor RBCs are often completely destroyed. The reason for this is obvious when new
antibodies directed against the transfused units are observed. However, alloantibodies may not
be detected at the time of the DHTR, may become detected later, or may never be detected.6
The worsening anemia probably represents a combination of hemolysis of transfused cells,
hyperhemolysis related to the immunologic response, and suppression of erythropoesis.19–22
The so-called “bystander hemolysis” may be a major mechanism in DHTR in SCD. In this
situation, one observes immune hemolysis of RBCs that are negative for the antigen against
which the relevant antibody is directed.21 Bystander hemolysis during DHTR may occur
following activation of complement as a result of the reaction of alloantibodies with transfused
RBCs or other antibody reactions with transfused foreign antigens, leading to the attachment
of activated complement components to autologous RBCs.6
The suppression of erythropoeisis that accompanies transfusion may also contribute to the
increased anemia observed following a DHTR.19 Marked reticulocytopenia is not always a
feature of DHTR,18, 23 although many patients have reticulocyte counts that are lower than
their baseline values. As patients with SCD have a shortened RBC survival, suppression of
erythropoiesis has a profound effect on hemoglobin concentration compared to patients with
normal red cell lifespan. Based on the finding of erythroid hyperplasia on a bone marrow
aspirate during a DHTR, a more recent case report suggests that the observed reticulocytopenia
during the course of a DHTR is not due to suppression of erythropoiesis, but rather is likely
due to peripheral consumption.22 While no experimental data were provided, the authors
postulated that the increased RBC destruction and reticulocytopenia during DHTR may be due
to the hyperactivity of macrophages.
The exposure of phosphatidylserine (PS) in RBC has recently been reported to be significantly
increased following the incubation of donor RBC with pre-transfusion plasma samples from
SCD patients who develop DHTR compared to other SCD patients who do not develop this
complication.24 Furthermore, the exposure of PS in RBC progressively increased in patients
with DHTR, particularly when donor erythrocytes were completely destroyed. As PS exposure
is a signal for apoptosis, this increased RBC PS exposure may contribute to the increased
hemolysis observed during DHTR.25 The role of PS in RBC adhesion to endothelium may
also, at least in part, explain the severe pain episodes observed during DHTR.26
Diagnosis
The diagnosis of DHTR is based on an appropriate history and laboratory testing. A DHTR
should always be in the differential diagnosis whenever a patient with SCD presents with
symptoms consistent with a pain crisis and decreasing hemoglobin approximately 5–10 days
following a transfusion of RBC. In addition to a complete blood count with reticulocyte count,
laboratory evaluation should include an antibody screen (indirect antiglobulin test) and direct
antiglobulin test to detect new RBC alloantibodies and/or autoantibodies, chemistries such as
serum bilirubin (total and indirect) and lactate dehydrogenase to assess for increased hemolysis,
and a urine sample to evaluate for hemoglobinuria. Inability to identify a new antibody does
not exclude the diagnosis of a DHTR, and in many cases, the antibody screen remains negative.
20 A hemoglobin electrophoresis is also helpful in establishing the diagnosis of a DHTR.
Hemoglobin electrophoresis often demonstrates total or near total destruction of donor
erythrocytes, indicated by a lack of hemoglobin A in the specimen.6
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There are no controlled studies that define the optimal treatment for DHTR in SCD. Whenever
a DHTR is suspected, further RBC transfusion should be withheld unless absolutely necessary,
as it may precipitate acceleration of the hemolytic reaction. The volume and frequency of blood
draws should be minimized. High dose steroids appear to be important 20 and for complicated
cases, IVIG should be considered, usually with the supervision of a hematologist. We have
also used high doses of erythropoietin, although baseline levels are likely to be elevated in
patients with normal renal function. Pain episodes and other complications associated with
DHTR should be treated as required.
Immune-modulating medications provide an exciting possibility for new modalities of
prevention for DHTR. Although clinical trials are lacking, a case report presented a patient
with three prior episodes of DHTR for whom rituximab, a monoclonal antibody that targets B
cells by binding CD20, allowed successful transfusion.27 This will likely be an active area of
research in upcoming years.
Minimizing RBC transfusion and the use of more extensive phenotypic matching of blood,
particularly the Rh and Kell blood group systems,28 when transfusion is required are essential
to decrease the risk of alloimmunization.7, 29 Although this is costly, transfused patients should
receive at the minimum, leukocyte-reduced RBC units that are E-, C-, and Kell-negative.2, 3,
28, 30
RBC transfusion can increase blood viscosity to a greater degree in patients with SCD than in
normal patients, thereby paradoxically decreasing the oxygen-carrying capacity at some levels.
2 As a result, every effort should be made to ensure that post-transfusion hemoglobin levels
do not exceed 10–11g/dL. Finally, patients should be educated about DHTR, providing them
with a letter (or card) that explains this complication and listing any known alloantibodies, so
that unnecessary transfusions are avoided by medical providers who are otherwise not familiar
with the patient’s medical history.
Conclusions
DHTR is an important complication of transfusions in SCD and should be considered whenever
a patient with SCD presents approximately 5–10 days after a transfusion with a decreasing
hemoglobin level and symptoms consistent with a pain crisis. It appears to result from a
destruction of transfused cells, suppression of erythropoiesis, and destruction of autologous
red cells. Further research on genetic associations with DHTR will likely provide considerable
help in elucidating risk factors, and perhaps information on the pathogenesis, of this syndrome.
The early identification of patients likely to develop alloantibodies could lead to focused, cost-
effective transfusion strategies by limiting the use of phenotypically matched RBCs to those
at greatest risk. Once a DHTR is suspected, further RBC transfusion should be withheld, unless
absolutely necessary. The optimal treatment for DHTR is not defined. However, many patients
appear to respond to treatment with high-dose steroids, with or without intravenous
immunoglobulin. More studies are needed to define the optimal treatment for this life-
threatening complication in SCD.
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Table 1
Components of Delayed Hemolytic Tranfusion Reactions*
Clinical Presentation
Manifestations of an acute or delayed hemolytic transfusion reaction
Symptoms suggestive of a sickle cell pain crisis associated with the hemolytic transfusion reaction
Diagnosis
Reticulocytopenia/fall from the patient’s baseline reticulocyte count
Development of a more severe anemia after transfusion than was present before it.
Serologies may not provide an explanation for the hemolytic reaction (i.e., no mismatch of blood products or new
alloantibody may be demonstrated)
Clinical Management
Further transfusion can worsen the anemia
Finding compatible units of RBCs may be challenging because of multiple alloantibodies or coexisting
autoantibodies. Some patients do not have demonstrable alloantibodies or are easy to crossmatch.
Recovery of reticulocytosis and increasing RBC counts may only occur if transfusion is withheld. Steroids are
important therapies in some patients.
Follow-up/Future Management
After recovery, further transfusion may cause recurrence of delayed hemolytic transfusion reaction.
*
Adapted from Petz L, Calhoun L, Shulman I, et al. The sickle cell hemolytic transfusion reaction syndrome. Transfusion. 1997;37:382–392.













Scheunemann and Ataga Page 8
Table 2
Proposed Mechanisms for Development of More Severe Anemia Following Transfusion
Proposed Mechanism Reference
1. Suppression of erythropoiesis Petz et al, 1997
2. Immune-mediated destruction of autologous red cells (“bystander
hemolysis) King et al, 1997
3. Destruction by hyperactivated macrophages Win et al, 2001
4. Increased RBC exposure of phosphatidylserine Lang et al, 2005
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